The Best Target & The Best Chemical


FAK (Focal Adhesion kinase) plays an important role in signal transduction involved in cell migration, proliferation and differentiation by regulating cell growth and adhesion to extracellular matrix in normal and tumor cells. It is known that mutation of the FAK gene causes the loss of the interaction between the cell and the extracellular matrix, leading to metastasis of cancer cells. PHI-301 is a FAK inhibitor and is being developed as a drug to treat metastatic cancer by inhibiting abnormal signal transduction between cells and extracellular matrix.

Unmet needs
  • 68% of ovarian cancer
    patients have FAK

  • The need for a therapeutic
    agent with a mechanism that
    inhibits the primary tumor in
    the ovary from metastasis
    to the peritoneum
    through the EMT process.


Development of targeted therapy for metastatic ovarian cancer for patients with FAK overexpression

  • Basic experiment result
  • Number of patients About 430,000 people
  • Market size KRW 1.5T (2023) Target Market
    • Platinum-resistant/refractory ovarian cancer
    • Patients with P53 mutation or EGFR overexpression

Sources : Ovarian cancer-Forecast: Datamonitor, Healthcare DMKC0177115